InTandem delivers individualized, progressive rhythmic auditory stimulation (RAS) therapy in the home setting. It produces gait quality and speed improvements for post-stroke patients. This improves health outcomes and reduces the risk of adverse health events common in this patient population.
The system leverages wearable, clinical-grade gait sensors and a hardware control unit with adaptive algorithms. It effectively automates the key principles of RAS therapy in combination with best practices for neurorehabilitation interventions. MedRhythms says the system enables patients to access evidence-based intervention independently and at home.
CMS finalized the preliminary pricing determination for InTandem. This means payments would be made on a capped rental basis, with monthly Medicare payment amounts based on the commercial pricing for InTandem. CMS established a new Healthcare Common Procedure Coding System (HCPCS) code for InTandem. This code (E3200, “Gait modulation system, rhythmic auditory stimulation, including restricted therapy software, all components and accessories, prescription only”) comes alongside a Medicare benefit category determination of durable medical equipment (DME).
MedRhythms says the new pricing determination goes into effect for InTandem claims with date of service on or after April 1, 2025.
“We founded MedRhythms and developed InTandem to bring an innovative, transformational device into the lives of people living with chronic stroke walking impairments,” said Brian Harris, MedRhythms’ CEO and co-founder. “Achieving this key milestone is another crucial step in ensuring patients in need can access InTandem. We thank CMS for their consideration.”
